Voyager Therapeutics, Inc.

Contributing Author

Recent Articles by Voyager Therapeutics, Inc.

May-13	Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 VYGR GlobeNewswire
May-07	Voyager Reports First Quarter 2026 Financial and Operating Results VYGR -5.04% GlobeNewswire
Apr-27	Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease VYGR GlobeNewswire
Mar-09	Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results VYGR +21.65% VYGR +5.38% GlobeNewswire
Feb-09	Voyager to Present at Upcoming Investor Conferences VYGR GlobeNewswire
Nov-10	Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia VYGR GlobeNewswire
Nov-10	Voyager Reports Third Quarter 2025 Financial and Operating Results VYGR GlobeNewswire
Aug-26	Voyager to Present at Upcoming Investor Conferences VYGR GlobeNewswire
Aug-06	Voyager Reports Second Quarter 2025 Financial and Operating Results VYGR -5.29% VYGR GlobeNewswire
Jul-16	Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach VYGR +6.34% GlobeNewswire
Jun-10	Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference VYGR GlobeNewswire
May-15	Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication VYGR GlobeNewswire
May-06	Voyager Reports First Quarter 2025 Financial and Operating Results VYGR -6.88% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)